COLLABORATIVE RESEARCH
Uniting experts
Connecting data
Driving progress
Focus
Our main focus is on AML, ALL, CML, and MM, but we warmly welcome collaboration opportunities in other disease areas with unmet needs.
AML
Acute Myeloid Leukemia
AML is an aggressive haematologic malignancy characterised by the rapid expansion of abnormal myeloid precursor cells in the bone marrow. It disrupts normal haematopoiesis and presents with cytopenias, infections, or bleeding. AML is more common in older adults and has a highly heterogeneous biology.
Recent advances include improved genomic classification, targeted therapies such as FLT3 and IDH inhibitors, and growing use of measurable residual disease (MRD) to guide treatment.
While intensive chemotherapy remains a standard approach for many, new regimens and real–world data are reshaping strategies for both high–risk and older patients.
MM
Multiple Myeloma
MM is a plasma cell malignancy characterised by clonal proliferation in the bone marrow, with systemic effects such as bone damage and immune suppression. It primarily affects older adults and remains incurable, but survival has improved significantly due to rapid therapeutic advances.
Emerging treatments such as CAR–T cell therapies, bispecific antibodies, and targeted combination regimens are redefining care. Achieving and sustaining measurable residual disease (MRD) negativity is an increasingly important treatment goal.
Real–world data play a critical role in optimising treatment sequencing, assessing long–term outcomes, and supporting personalised approaches in this evolving field.
ALL
Acute Lymphoblastic Leukemia
ALL is a rapidly progressing malignancy of lymphoid precursor cells that impairs normal blood formation. It is most common in children but also affects adults, where outcomes have historically been poorer.
Molecular profiling, targeted agents like tyrosine kinase inhibitors for Ph-positive disease, and the use of MRD to guide therapy have significantly improved outcomes. In relapsed or refractory cases, immunotherapies such as CAR-T cells and bispecific antibodies are offering new options.
Treatment is increasingly risk-adapted and data-driven, aiming for durable remissions and long-term survivorship across age groups.
CML
Chronic Myeloid Leukemia
CML is a myeloproliferative neoplasm caused by the BCR-ABL1 fusion gene, which drives uncontrolled myeloid cell proliferation.
Tyrosine kinase inhibitors (TKIs) have transformed CML into a chronic condition for many patients, with survival approaching that of the general population. Molecular monitoring is central to treatment, guiding both dose adjustments and potential discontinuation.
Treatment-free remission has become a realistic goal for selected patients. Ongoing research focuses on optimising sequencing, managing resistance, and improving quality of life over the long term.
+ Other haematological malignancies
The HARMONY Platform also supports research into myeloproliferative neoplasms (MPN), non-Hodgkin lymphomas (NHL), myelodysplastic syndromes (MDS), and acute promyelocytic leukaemia (APL). These heterogeneous malignancies benefit from collaborative efforts to improve risk stratification, optimise treatment strategies, and generate robust outcome data using harmonised real-world evidence.
Publications in high-impact scientific journals
The HARMONY Alliance Foundation’s publications reflect the shared expertise and collaborative efforts of our research community. They present innovative methodologies and data-driven insights that help address some of the most urgent challenges in haematological malignancies.
From improving diagnostic accuracy to enabling more personalised treatment strategies, these studies contribute to the global scientific knowledge base and reinforce the Foundation’s role as a leading voice in haematology research.
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Real-world evaluation of UK high hyper diploidy profile using a large cohort of patients provided by HARMONY data platform
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Our Data Partners
A powerful network driving progress in haematology
The HARMONY Alliance Foundation brings together one of the largest collaborative networks in global haematology — uniting data partners, hospitals, academic groups, and research organisations across more than 20 countries. This trusted community is the foundation of our success: sharing data, expertise, and a commitment to improving outcomes through collective insight.
Participation in EU initiatives
Collaborating with the HARMONY Alliance Foundation means joining forces with one of Europe’s largest haematology data platforms, a trusted network of leading experts, and a proven track record in successful EU-funded projects.
We bring distinctive strengths in data harmonization, advanced analytics and real-world evidence generation. This helps you build stronger, more competitive proposals with greater scientific and societal impact.
Darwin EU
A EMA initiative delivering real-world evidence from across Europe to support regulatory decision-making on the safety and effectiveness of medicines.
Resolve
A multinational project establishing MRD as a treatment-guiding biomarker in AML and CLL through standardised diagnostics, a patient registry, and a pragmatic clinical trial.
IMPACT-AML
A European initiative creating a master framework for relapsed or refractory AML, conducting a pragmatic clinical trial comparing high- and low-intensity therapies to optimise treatment strategies.
Miracle
A Marie Skłodowska-Curie doctoral network training researchers to combat MRD in leukaemia by integrating multi-omics data and developing novel targeted therapies.